On this page
Quick Reference
Overview and Recommendations
Background
- •Early palliative care (EPC) integrated with standard oncology care at diagnosis of advanced NSCLC improves quality of life (mean FACT-L 98.0 vs 91.5), reduces depressive symptoms (16% vs 38% at 12 weeks), and is associated with a median survival benefit of 2.7 months (11.6 vs 8.9 months), the foundation of the Temel trial (2010) that changed practice.
- •The American Society of Clinical Oncology (ASCO) provisional clinical opinion recommends that patients with metastatic non-small-cell lung cancer be offered concurrent palliative care and standard oncologic care at initial diagnosis, and the NCCN guidelines similarly emphasize a multidisciplinary team approach.
- •EPC optimizes end-of-life care: patients receiving EPC have half the odds of receiving chemotherapy within 60 days of death (OR 0.47), a longer interval from last intravenous chemotherapy to death (median 64 vs 40.5 days), and higher enrollment in hospice for >1 week (60% vs 33.3%).
- •Alternative delivery models have been validated: video visits (REACH trial) are equivalent to in-person for QOL, while a stepped-care model (visits triggered by QOL decline) is noninferior for QOL but results in fewer hospice days (19.5 vs 34.6), suggesting that less intensive palliative care may compromise end-of-life continuity.
- •The survival benefit of EPC has been replicated globally: the PACO trial in Mexico (median OS 18.1 vs 10.5 months) and the E-warm interdisciplinary model in China (24.6 vs 20.4 months; HR 0.19) confirm that early integration improves outcomes across diverse healthcare settings.
Evaluation
- •Suspect the need for palliative care integration in every patient with newly diagnosed advanced NSCLC, regardless of symptom burden, the evidence supports initiating EPC within 8 weeks of diagnosis, not waiting for symptom escalation.
- •Ask about the four cardinal symptoms that drive palliative intervention: dyspnea (exertional and at rest), cough with or without hemoptysis, pain (site, severity, character), and fatigue. Quantify pain on a 0-10 numeric rating scale.
- •Assess hemoptysis risk in detail before any antiangiogenic therapy: inquire about episodes of bright red blood ≥2.5 mL within the past 3 months and document tumor histology (squamous vs non-squamous). Both are absolute contraindications to bevacizumab.
- •Examine performance status using the ECOG scale (0-5), better status predicts response to palliative thoracic radiotherapy (OR per point 0.71), and document weight loss, which may guide nutritional support and prognosis.
- •Order baseline quality-of-life assessment with the FACT-L (Functional Assessment of Cancer Therapy-Lung) and depression screening with the PHQ-9 or equivalent. The Temel trial used these tools to track outcomes.
- •For patients with brain metastases not eligible for stereotactic radiosurgery (SRS) or surgical resection, evaluate for whole-brain radiotherapy (WBRT) vs optimal supportive care alone using the QUARTZ trial criteria: no survival or QOL benefit from WBRT in this group, so dexamethasone alone is a reasonable default.
- •Assess prognostic awareness through repeated conversations about incurability, a single disclosure is insufficient. Patients who have had both recent and past discussions are 5 times more likely to have accurate awareness at 3 months (AOR 5.08), which reduces preference for life-prolonging treatment (AOR 0.39).
- •Evaluate caregiver burden systematically using the Zarit Burden Interview; a score ≥29 indicates mild-moderate burden. Identify caregivers providing >6 hours of daily care, as this is associated with significantly lower health-related quality of life.
- •Order chest CT for any patient with hemoptysis to identify the bleeding site and assess for tumor cavitation (OR 9.6 for severe pulmonary hemorrhage with bevacizumab). Bronchoscopy may be needed for central airway obstruction.
- •In the end-of-life phase, assess for terminal symptoms: dyspnea, pain, death rattle, and delirium. Use validated tools like the Edmonton Symptom Assessment System (ESAS) to track symptom burden daily.
Management
- •Initiate early palliative care referral within 8 weeks of diagnosis of advanced NSCLC, with scheduled visits at least monthly, this is the protocol that produced the survival and QOL benefits in the Temel trial.
- •For hemoptysis, first exclude contraindications to bevacizumab: do not administer bevacizumab in patients with predominantly squamous histology or a history of clinically significant hemoptysis (≥2.5 mL within 3 months). If cavitation is present, consider an alternative antiangiogenic agent.
- •In severe pulmonary hemorrhage, immediately stabilize the airway (endotracheal intubation), correct hypoxia, support blood pressure, and transfuse as needed. Then perform bronchoscopic therapy (rigid bronchoscopy preferred for massive bleeding) or bronchial artery embolization (BAE), first-line for persistent hemorrhage, achieving 89% immediate symptom palliation.
- •Administer external beam radiotherapy (short course, 2-5 fractions) for hemoptysis palliation; it resolves hemoptysis in ≥70% of patients with unresectable lung cancer.
- •Permanently discontinue bevacizumab in any patient who develops grade 3 or 4 bleeding.
- •For pain management, follow the WHO ladder: opioids are first-line for moderate-to-severe pain. For dyspnea, use morphine 2.5-5 mg orally or intravenously every 4 hours as needed; add benzodiazepines if anxiety is present.
- •Avoid the combination of erlotinib (150 mg daily) with COX-2 inhibitors (e.g., celecoxib 400 mg BID) in patients with a history of peptic ulcer disease or those requiring therapeutic anticoagulation, this combination caused grade 3/4 upper GI bleeding in 15% of patients in a phase II trial.
- •For brain metastases unsuitable for SRS or surgery, manage with dexamethasone alone and omit whole-brain radiotherapy (WBRT). The QUARTZ trial showed no difference in survival (HR 1.06), quality of life, or dexamethasone use; mean QALY difference was only 4.7 days, meeting non-inferiority criteria.
- •For palliative thoracic radiotherapy, use doses >30 Gy (e.g., 39 Gy in 13 fractions or 42 Gy in 15 fractions with concurrent chemotherapy) for better survival. For tumors >7 cm, concurrent chemoradiotherapy (42 Gy/15 fractions) improves median survival from 9.7 to 13.4 months (p=0.001).
- •For endobronchial brachytherapy (HDR-EBIRT), expect 87.7% complete or major symptom response within 3 months for central airway obstruction. Median survival is 13 months in responders vs 7 months in non-responders. Fatal hemoptysis occurs in 7.8%.
- •For bone metastases, use single-fraction radiotherapy (8 Gy) for pain palliation, it is as effective as multi-fraction regimens and preferred in the palliative setting to minimize patient visits.
- •For adrenal metastases, use stereotactic body radiotherapy (SBRT) with BED10 ≥50 Gy (≤12 fractions) for superior 1-year freedom from local progression compared with palliative RT.
- •For sleeve lobectomy with microscopic residual disease (R1), avoid converting to pneumonectomy; adjuvant radiotherapy improves overall survival and reduces distant recurrence.
- •In end-of-life care, manage terminal secretions (death rattle) with anticholinergics: glycopyrrolate 0.2-0.4 mg IV/SC every 4-6 hours as needed, or scopolamine 1.5 mg transdermal patch every 72 hours.
- •Treat delirium with haloperidol 0.5-2 mg orally or IV every 6-8 hours as needed; search for reversible causes such as opioid neurotoxicity, hypercalcemia, or infection.
- •Withdraw non-beneficial treatments (chemotherapy, IV fluids, artificial nutrition) when burdens outweigh benefits. Ensure equity in end-of-life care, patients with dementia receive less opioid use and fewer palliative care consultations; actively address these disparities.
- •Use disease-centred advance directives that detail NSCLC-specific complications (e.g., hemoptysis, dyspnea) to improve physician concordance with patient wishes (concordance 0.83 vs 0.60 for generic directives).
- •Engage caregivers in repeated discussions about incurability and prognosis; provide psychosocial support through mind-body interventions (e.g., brief couple-based interventions, yoga programs) which have shown large effect sizes for reducing sleep disturbances (d=1.83) and depressive symptoms in partners (d=0.90).
- •Refer to hospice when prognosis is ≤6 months; early palliative care increases the likelihood of hospice enrollment >1 week (NNT=4) and reduces aggressive end-of-life care (NNT=5). The stepped-care model, while scalable, may compromise hospice days (19.5 vs 34.6).
- •Monitor for esophagitis in patients receiving hypofractionated palliative RT (30-54 Gy, 2.5-4 Gy/fraction): 31% develop esophagitis (26% grade 2-3). Concurrent chemotherapy increases risk; oral steroids reduce it. Esophageal Dmax ≥40 Gy is the strongest predictor, and Dmean ≤20 Gy is protective.
Board Review — High Yield
- •Early Palliative Care, Initiated within 8 weeks of diagnosis of advanced NSCLC; improves QOL, reduces depression, and prolongs survival (Temel trial: 11.6 vs 8.9 months).
- •Bevacizumab contraindication, Squamous histology or hemoptysis ≥2.5 mL within 3 months; cavitation increases risk of severe pulmonary hemorrhage (OR 9.6).
- •QUARTZ trial, Omit whole-brain radiotherapy in NSCLC brain metastases unsuitable for SRS/surgery; no survival or QOL benefit over dexamethasone alone.
- •Bronchial artery embolization, First-line for persistent pulmonary hemorrhage; 89% immediate symptom palliation.
- •Prognostic awareness, Repeated discussions about incurability improve accurate awareness (AOR 5.08) and reduce preference for life-prolonging treatment (AOR 0.39).
- •Caregiver burden, 62.6% report mild-moderate burden; >6 hours daily care lowers HRQoL; mind-body interventions show large effect sizes.
- •Single-fraction RT, 8 Gy for bone metastases pain palliation; as effective as multi-fraction and preferred in palliative setting.
- •HDR-EBIRT, Endobronchial brachytherapy yields 87.7% symptom response for central airway obstruction; fatal hemoptysis risk 7.8%.
- •Stepped-care model, Noninferior for QOL but associated with fewer hospice days (19.5 vs 34.6), suggesting less intensive palliative care may compromise end-of-life continuity.
- •Disease-centred advance directives, Improve physician concordance with patient wishes (0.83 vs 0.60 for generic directives).
Deep Dive — Evidence Details
When to Integrate Palliative Care
- ▸Early palliative care integrated at diagnosis of advanced NSCLC improves quality of life, reduces depressive symptoms, and prolongs survival compared with standard oncology care alone.
- ▸ASCO recommends offering concurrent palliative care and standard oncologic care at initial diagnosis for patients with metastatic NSCLC.
- ▸The survival benefit of early palliative care is not mediated by improvement in depression, but depression itself is a significant predictor of worse survival.
Palliative care should be integrated early in the course of (NSCLC), beginning at the time of diagnosis of advanced disease. The landmark randomized trial of 151 patients with newly diagnosed metastatic NSCLC demonstrated that early palliative care (EPC) integrated with standard oncology care, compared with standard care alone, improved quality of life (mean FACT-L score 98.0 vs 91.5; P=0.03), reduced depressive symptoms (16% vs 38%; P=0.01), and was associated with longer median survival (11.6 months vs 8.9 months; P=0.02) [6]A1b. Although the survival benefit was not mediated by depression improvement, depression itself predicted worse survival (HR 1.82; 95% CI 1.10-3.01; P=0.02) and EPC produced greater depression response rates at 12 weeks (42.9% vs 0%; P=0.04) [3]A1b.
The Evidence for Early Integration
EPC also optimizes end-of-life care. In a secondary analysis, patients receiving EPC had half the odds of receiving chemotherapy within 60 days of death (OR 0.47; 95% CI 0.23-0.99; P=0.05), a longer interval between last intravenous chemotherapy and death (median 64 vs 40.5 days; P=0.02), and higher enrollment in hospice for longer than 1 week (60% vs 33.3%) [4]A1b. Furthermore, EPC significantly improved patients' accurate understanding of their prognosis over time compared with standard care (82.5% vs 59.6%; P=0.02), and those with accurate perceptions were less likely to receive intravenous chemotherapy near the end of life (9.4% vs 50%; P=0.02) [5]A1b.
How Early and What Models?
EPC is initiated within 8 weeks of diagnosis, with scheduled visits at least monthly [6]A1b. More recent trials have explored alternative delivery models to improve access. The REACH trial demonstrated that delivering EPC via video visits is equivalent to in-person visits for quality of life at 24 weeks (mean FACT-L 99.7 vs 97.7; difference 2.0; 90% CI 0.1-3.9; P=0.04 for equivalence) [12]A1b. A stepped-care model, with visits triggered by a 10-point or greater decline in QOL, achieved noninferior QOL outcomes with fewer visits (mean 2.4 vs 4.7) but was associated with fewer days in hospice (19.5 vs 34.6; for noninferiority) [13]A1b. The PACO trial, conducted in a resource-limited setting in Mexico, confirmed a survival benefit (median OS 18.1 months vs 10.5 months; P=0.029), with the greatest benefit in patients with baseline global QOL >70 [14]A1b. A Chinese trial using the E-warm interdisciplinary model also showed longer OS (24.6 vs 20.4 months; HR 0.19; 95% CI 0.04-0.85; P=0.029) and improved QOL, pain, and nutrition [17]A1b.
Guideline Recommendations
Based on this evidence, the American Society of Clinical Oncology (ASCO) provisional clinical opinion states that "patients with metastatic non-small-cell lung cancer should be offered concurrent palliative care and standard oncologic care at initial diagnosis" [11]B2b. The ASCO panel further recommends that combined standard oncology care and palliative care should be considered early in the course of illness for any patient with metastatic cancer and/or high symptom burden [11]B2b. NCCN guidelines similarly emphasize a multidisciplinary team approach to care [16]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Optimal delivery model: stepped vs early palliative care | Stepped care is noninferior for QOL and more scalable [13]A1b | Early care (monthly visits) remains standard for ensuring adequate hospice days [6]A1b | Step-care may reduce workforce burden but could compromise end-of-life care intensity [13]A1b | Clinicians should consider patient preferences and local resources when choosing between models |
Pearl: Initiate a palliative care referral within 8 weeks of diagnosis for all patients with advanced NSCLC, regardless of symptom burden, as early integration improves quality of life, mood, and survival, and optimizes end-of-life care.
| Trial (Year) | N | Intervention | Key Results |
|---|---|---|---|
| Temel et al. (2010) [6]A1b | 151 | EPC integrated with standard oncology care vs standard care alone | Improved QOL (mean FACT-L 98.0 vs 91.5; P=0.03), fewer depressive symptoms (16% vs 38%; P=0.01), longer median survival (11.6 vs 8.9 months; P=0.02) |
| PACO (2024) [14]A1b | 146 | EPC + standard care vs standard care alone in Mexico | Median OS 18.1 vs 10.5 months (P=0.029); greatest benefit in patients with baseline QOL >70 |
| Chen et al. (2023) [17]A1b | 280 | Combined early palliative care (E-warm model) vs standard care | Longer OS (24.6 vs 20.4 months; HR 0.19; 95% CI 0.04-0.85; P=0.029), improved QOL, pain, nutrition |
| REACH (2024) [12]A1b | 1250 | Video vs in-person EPC | Equivalent QOL at 24 weeks (mean 99.7 vs 97.7; difference 2.0; 90% CI 0.1-3.9; P=0.04 for equivalence) |
Symptom Management
- ▸Baseline tumor cavitation is the only radiographic predictor of severe pulmonary hemorrhage in bevacizumab-treated patients; central tumor location is not a risk factor in non-squamous NSCLC.
- ▸Maintenance pemetrexed delays worsening of pain and hemoptysis compared with placebo, though it increases loss of appetite and transfusion requirements.
- ▸The combination of erlotinib with celecoxib carries a 15% risk of grade 3/4 upper GI bleeding in patients with peptic ulcer disease or on anticoagulation.
Once the decision to integrate palliative care is made, the focus shifts to active symptom palliation, with hemoptysis and pain representing two of the most distressing and common symptoms in advanced NSCLC.
Risk Stratification for Hemoptysis
Hemoptysis is a presenting symptom in 30% to 60% of patients with lung cancer and is frequently the harbinger of severe pulmonary hemorrhage (PH) [24]D5. The risk of PH is substantially increased by a history of clinically significant hemoptysis (bright red blood ≥2.5 mL per event within 3 months before therapy) and by predominantly squamous histology, both of which excluded patients from the pivotal trials [24]D5. In the phase III 4599 trial, which excluded these groups, the incidence of grade ≥3 PH was 1.9% among bevacizumab recipients (fatal in 1.2%), compared with 0.2% in the chemotherapy-alone arm [24]D5. The retrospective case-control analysis of ECOG 4599 identified baseline tumor cavitation as the only radiographic predictor of severe PH (odds ratio [OR] 9.6; 95% CI 0.86-107.64; P = 0.034) [23]B2b. Central tumor location was not a significant risk factor, and patients with non-squamous NSCLC should not be excluded from bevacizumab solely on the basis of a central tumor [23]B2b[24]D5.
| Risk Factor | Recommendation | Strength of Evidence |
|---|---|---|
| Predominantly squamous histology | Do not administer bevacizumab | Excluded from phase III trials [24]D5 |
| History of hemoptysis ≥2.5 mL within 3 months | Do not administer bevacizumab | Excluded from phase III trials [24]D5 |
| Baseline tumor cavitation | Consider alternative antiangiogenic; increased PH risk (OR 9.6) | Retrospective case-control, small numbers [23]B2b |
| Central tumor location (non-squamous) | Does not preclude bevacizumab | Multiple studies show no significant association [23]B2b[24]D5 |
Pain Management
Pain is a cardinal symptom in advanced NSCLC. In the phase III H3E-MC-JMEN trial, maintenance pemetrexed (500 mg/m² every 21 days) after platinum-based induction significantly delayed the time to worsening of pain on the Lung Cancer Symptom Scale compared with placebo (hazard ratio [HR] 0.76; 95% CI 0.59-0.99; P = 0.041; NNT not calculable from reported data) [22]A1b. The same study also reported a delayed worsening of hemoptysis with pemetrexed (HR 0.58; 95% CI 0.34-0.97; P = 0.038) [22]A1b. These benefits occurred alongside a modest increase in loss of appetite (mean 4.3 mm vs 0.2 mm on 100-mm scale; P = 0.028) and higher rates of transfusions (10% vs 3%) and erythropoiesis-stimulating agent use (6% vs 2%) [22]A1b.
Concomitant use of COX-2 inhibitors with erlotinib may increase the risk of upper gastrointestinal bleeding, particularly in patients with a history of or those requiring therapeutic anticoagulation. In a phase II trial of erlotinib 150 mg daily plus celecoxib 400 mg orally twice daily, 4 of 26 patients (15%) developed grade 3/4 upper GI bleeding, prompting early study closure [25]B2b. The authors advise excluding patients with peptic ulcer disease or anticoagulation requirement from such combinations [25]B2b.
Management of Pulmonary Hemorrhage
Severe PH is a medical emergency. An ESMO expert consensus panel recommends the following approach [24]D5:
- Immediate actions: Airway maintenance with endotracheal intubation, cardiorespiratory monitoring, correction of hypoxia, blood pressure stabilization, and blood transfusion as needed [24]D5.
- Imaging: High-resolution chest CT to identify the bleeding site [24]D5.
- Bronchoscopic therapy: Rigid bronchoscopy is preferred for massive bleeding; flexible bronchoscopy can be used for therapeutic irrigation. Laser coagulation, electrocautery, and argon plasma coagulation are useful [24]D5.
- Bronchial artery embolization (BAE): First-line therapy for persistent PH, providing immediate symptom palliation in 89% of patients in one series, though recurrence is more common in cancer patients than in those with non-malignant PH [24]D5.
- Radiotherapy: (short course, 2-5 fractions) resolves hemoptysis in ≥70% of treated patients with unresectable lung cancer [24]D5.
- Permanent bevacizumab discontinuation: Bevacizumab should be stopped permanently in any patient who develops grade 3 or 4 bleeding [24]D5.
The combination of thoracic stereotactic ablative radiotherapy ( ) with VEGF inhibitors increases the risk of high-grade PH, particularly for ultracentral tumors (3-year incidence 45% with VEGFi plus SABR vs 9.0% with SABR alone; P = 0.044) [32]B2b. Clinicians should avoid this combination, especially when the tumor abuts the proximal bronchial tree.
Pearl: For patients with advanced NSCLC who develop hemoptysis, first exclude squamous histology and cavitation as risk factors for severe PH, then consider bronchial artery embolization or hypofractionated radiotherapy for palliation, while permanently discontinuing bevacizumab if grade ≥3 bleeding occurs.
Psychosocial, Spiritual, and Caregiver Support
- ▸Prognostic awareness improves with repeated discussions about incurability and reduces preference for life-prolonging treatment.
- ▸Dyadic mindfulness-based interventions (e.g., couple-based meditation) yield medium-to-large effect sizes for depressive symptoms and cancer-related stress in both patients and spouses.
- ▸Caregiver burden is substantial even in early-stage NSCLC; spousal caregivers and those providing >6 hours of daily care are at highest risk for decreased HRQoL.
Symptom management alone is insufficient to address the full burden of advanced NSCLC; psychosocial distress, existential suffering, and caregiver strain are core domains that demand systematic assessment and evidence-based intervention. The following sections review the evidence for prognostic-awareness communication, psychosocial and spiritual interventions, and caregiver support.
Prognostic Awareness and Communication
Accurate prognostic awareness among patients with advanced NSCLC is poor and often discordant with caregivers' expectations. In a prospective cohort of 200 patients with pretreated advanced NSCLC, only 54% of patients and 51% of caregivers had accurate awareness at baseline [41]B2b. Patients who had both recent and past discussions about incurability with their oncologist were significantly more likely to have accurate awareness 3 months later (adjusted odds ratio 5.08; 95% CI, 1.31-19.78) compared with those informed only recently [41]B2b. Critically, accurate awareness at 3 months was associated with a lower preference for life-prolonging treatment (adjusted odds ratio 0.39; 95% CI, 0.17-0.90) [41]B2b. These findings emphasize that a single disclosure is insufficient; repeated, longitudinal conversations about incurability are needed to align patient understanding with clinical reality and reduce futile treatment preferences.
Psychosocial and Spiritual Interventions
Several dyadic, mindfulness-based, and educational interventions have been pilot-tested for patients with advanced NSCLC and their partners.
- Brief couple-based mind-body intervention: A single-arm pilot reported large effect sizes for reduced sleep disturbances (d = 1.83) and medium for cancer-specific distress (d = 0.61) in patients, and large for depressive symptoms in partners (d = 0.90) [51]C4.
- Vivekananda Yoga program: A 15-session dyadic program showed a significant increase in patients' mental health (d = 0.84; P =.04) and a significant decrease in caregivers' sleep disturbances (d = 1.44; P =.02) [50]B2b.
- Wellness education: In two RCTs of patients receiving icotinib, 8-12 weeks of wellness education improved emotional well-being, anxiety, caregiver adaptation, and family cohesion (P < 0.05) [43]A1b[47]A1b.
- Interdisciplinary palliative care: Among 491 patients with stage I-IV NSCLC, an interdisciplinary educational intervention significantly improved QOL (109.1 vs. 101.4; P < 0.001), spiritual well-being (38.1 vs. 36.2; P = 0.001), and distress (2.2 vs. 3.3; P < 0.001), and increased advance care directive completion (44% vs. 9%; P < 0.001) [49]B2b.
Spiritual faith may also influence treatment outcomes; a small study of 50 patients found that those with a high degree of faith had a significantly higher tumor response rate and 3-year survival, though these findings are preliminary and require replication [55]B2b.
Caregiver Burden and Support
Caregiver burden is substantial across all stages of NSCLC. In early-stage disease, the mean Zarit Burden Interview score was 29.1 ± 11.4, with 62.6% of caregivers reporting mild to moderate burden [56]B3b. Significant predictors included duration of caregiving (β = 0.18, P <.001), passive coping (β = 0.17, P =.001), and anxiety (β = 0.13) [56]B3b. Among 553 caregivers of patients with advanced NSCLC, the mean EQ-5D-5L utility score was 0.92; 45.39% reported anxiety or depression, and spouses had the lowest health-related quality of life [57]B3b. Providing more than 6 hours of daily care was associated with significantly lower caregiver HRQoL [57]B3b.
In a European survey of 427 caregivers, the mean weekly support was 29.5 hours, and overall work impairment ranged from 21.1% (Germany) to 30.4% (France) [60]B3b. Caregivers of patients receiving later lines of therapy reported worse health status [60]B3b. Patient symptom burden is inversely correlated with caregiver benefit finding (r = -0.609 to -0.151; P < 0.05), indicating that effective symptom management may enhance positive caregiver experiences [58]B3b.
In a cross-sectional study of 333 patients, 36% of family caregivers expected a cure from palliative chemotherapy, highlighting the need for aligned communication about treatment goals [45]B3b. Caregivers and health care providers tend to perceive the psychosocial consequences of NSCLC as more severe than patients themselves do [54]D5. Shared decision-making preferences also show discordance: while 53% of clinicians believed patients wanted the doctor to make final decisions in later stages, only 11-12% of patients actually preferred that [59]B3b.
Pearl: Repeated discussions about incurability (not just a single disclosure) are associated with a 5-fold increase in accurate prognostic awareness, which in turn reduces preference for life-prolonging treatment [41]B2b.
| Study | Population | Main Burden Measure | Key Finding |
|---|---|---|---|
| Zhu et al. 2022 [56]B3b | Early-stage NSCLC, postsurgical | Zarit Burden Interview (ZBI) | Mean ZBI 29.1; 62.6% mild-moderate burden; predictors: duration, passive coping, anxiety |
| Yang et al. 2024 [57]B3b | Advanced NSCLC (stage IIIB-IV) | EQ-5D-5L | Mean utility 0.92; 45.39% anxiety/depression; spouses and >6 hr/day caregiving associated with lower HRQoL |
| Wood et al. 2018 [60]B3b | Advanced NSCLC, France/Germany/Italy | ZBI, WPAI | Mean 29.5 hr/week caregiving; work impairment 21-30%; worse health status in later-line caregivers |
| Ma et al. 2023 [58]B3b | NSCLC receiving combined chemotherapy | Benefit Finding Scale (BFS) | Symptom burden inversely correlated with benefit finding (r = -0.609 to -0.151) |
| Viñolas et al. 2020 [46]B3b | Metastatic NSCLC, Spain | Zarit, economic impact | No sex differences in economic burden; more parents as caregivers for female patients |
Palliative Procedures
- ▸Palliative thoracic radiotherapy provides symptom relief in ~70% of patients; response is best with ECOG 0-1 and EGFR-mutant tumors.
- ▸Whole-brain radiotherapy can be safely omitted in NSCLC patients with brain metastases unsuitable for resection or SRS, based on the QUARTZ trial.
Building on the psychosocial framework, clinicians now turn to procedural interventions that directly address the most burdensome symptoms of advanced NSCLC. Palliative procedures, radiotherapy, endobronchial , and selected surgical resections, are selected on the basis of symptom burden, performance status, and expected survival.
Palliative Thoracic Radiotherapy
For patients with incurable locally advanced or metastatic NSCLC, palliative thoracic radiotherapy (PTR) relieves cough, hemoptysis, dyspnea, and pain arising from intrathoracic disease. The overall response rate in an urgent-access clinic was 70.0% (95% CI 65.8-74.2) [69]B3b. Response is more likely in patients with better (OR per point 0.71, 95% CI 0.55-0.93) and EGFR-mutant tumors (OR vs. wild-type 2.46, 95% CI 1.35-4.51) [69]B3b.
Fractionation should be tailored to prognosis. The International Atomic Energy Agency randomized trial comparing 39 Gy in 13 fractions to chemotherapy followed by short-course RT (10 Gy × 1 or 16 Gy in 2 fractions) found no difference in median survival (7.1 vs. 8.1 months) or toxicity [64]A1b. A prospective study showed that RT doses ≤30 Gy are associated with significantly worse survival; doses >30 Gy and sequential chemotherapy improve outcomes [76]B3b. For poor-prognosis patients with stage III NSCLC and tumors larger than 7 cm, concurrent chemoradiotherapy (42 Gy/15 fractions) improved median survival from 9.7 to 13.4 months (p=0.001) and 1-year survival from 33% to 56% (p=0.01) compared with chemotherapy alone [65]A1b. The CONRAD trial confirmed that chemoradiation (42 Gy/15) yields superior survival (median 12.6 vs. 9.7 months, p<0.01; 1-year 53.2% vs. 34.0%, p<0.01) despite more hospitalizations [66]A1b.
Esophagitis is the main toxicity. In patients receiving hypofractionated palliative RT (30-54 Gy, 2.5-4 Gy/fraction), 31% developed esophagitis (26% grade 2-3, no grade 4-5). Concurrent chemotherapy significantly increased risk, while oral steroids reduced it. Esophageal Dmax ≥40 Gy was the strongest predictor; a Dmean ≤20 Gy was protective [73]B3b.
: WBRT vs. Supportive Care
The QUARTZ trial provides the strongest evidence for omitting whole-brain radiotherapy (WBRT) in NSCLC patients with brain metastases unsuitable for resection or . Patients received optimal supportive care (OSC) including with or without WBRT (20 Gy in 5 fractions). There was no difference in overall survival (HR 1.06, 95% CI 0.90-1.26), quality of life, or dexamethasone use. The mean quality-adjusted life-years difference was only 4.7 days (46.4 vs. 41.7 QALY days), meeting the non-inferiority criterion [63]A1b. Thus, OSC alone is a reasonable default for this group, reserving WBRT for patients with urgent neurological symptoms.
For patients with limited brain metastases, stereotactic radiosurgery ( ) is favored over WBRT to avoid neurocognitive decline. When WBRT is indicated, 20 Gy in 5 fractions is standard.
Endobronchial Brachytherapy
High-dose-rate endobronchial interventional radiotherapy (HDR-EBIRT) is effective for palliation of central airway obstruction, especially as re-irradiation. In a large series, 87.7% of patients had complete or major symptom response within 3 months. Median survival was 13 months in responders vs. 7 months in non-responders (p=0.03). OS was 55.2% at 1 year and 18.3% at 2 years. Fatal hemoptysis occurred in 7.8% [79]B3b.
Palliative Surgical Resection
For patients with central tumors requiring sleeve , microscopic residual disease (R1) is sometimes unavoidable. A propensity-matched study found that palliative sleeve lobectomy with R1 status (SLobR1) did not differ from in overall survival or progression-free survival, except in stage I disease where R1 was detrimental. Adjuvant radiotherapy improved overall survival and reduced distant recurrence, though it increased extrathoracic lymph node metastasis [70]B3b. Therefore, completing sleeve lobectomy rather than converting to pneumonectomy is acceptable, especially in patients with poor tolerance for extensive surgery.
Other Metastatic Sites
- Adrenal metastases: ( , ≤12 fractions, BED10 ≥50 Gy) yields superior 1-year freedom from local progression compared with palliative RT (BED10 <50 Gy). Toxicity is mild; adrenal insufficiency occurred in 4 of 326 patients [72]C4.
- Bone metastases: Single-fraction RT (8 Gy) is as effective as multi-fraction regimens for pain palliation and is preferred in the palliative setting to minimize patient visits [61]B2a. Surgery for impending or pathologic fractures of the proximal femur should maximize stability, with adjuvant RT to improve local control [77]B3b.
Pearl: For NSCLC patients with brain metastases unsuitable for surgery or SRS, omit whole-brain radiotherapy and manage with dexamethasone alone, the QUARTZ trial showed no survival or quality-of-life benefit from WBRT, saving patients from unnecessary treatment burden.
| Regimen | Total Dose | Fractions | Setting | Evidence |
|---|---|---|---|---|
| Short-course | 10 Gy | 1 | Poor prognosis, PS ≥2, urgent palliation | [61]B2a[64]A1b |
| Short-course | 16 Gy | 2 (separated by 1 week) | Alternative short-course | [64]A1b |
| Hypofractionated | 30 Gy | 10 | Moderate prognosis | [61]B2a[73]B3b |
| Hypofractionated | 42 Gy | 15 | Concurrent chemoradiation, poor prognosis stage III | [65]A1b[66]A1b |
| Moderate hypofractionation | 39 Gy | 13 | Protracted palliative monotherapy | [64]A1b |
End-of-Life Care and Hospice
- ▸Early palliative care increases hospice enrollment >1 week from 33% to 60% (NNT = 4) and reduces aggressive end-of-life care from 54% to 33% (NNT = 5) [4][6].
- ▸Disease-centred advance directives improve physician understanding of patient wishes (concordance 0.83 vs 0.60) [82]; repeated discussions about incurability improve prognostic awareness and reduce preference for life-prolonging treatment [41].
- ▸Despite evidence, 70% of patients still receive at least one aggressive care indicator in the last month of life [86]; hospice/palliative care unit admission mitigates the negative impact of such care on family satisfaction [93].
Following the procedures discussed in the previous section, the focus now shifts to the terminal phase: hospice enrollment, advance care planning, and management of refractory symptoms at the very end of life. The goal is to align care with patient values while minimizing aggressive, non-beneficial interventions.
Hospice and End-of-Life Care Transitions
Hospice eligibility requires a prognosis of ≤6 months, but clinicians often overestimate survival. Transition points can trigger timely referral: for NSCLC, the first admission with metastatic disease carries a median survival of 3.8 months (IQR 1.1-16.0) [90]C4. Early palliative care integration dramatically improves hospice outcomes. In the landmark Temel trial, patients receiving early palliative care were more likely to enroll in hospice for >1 week (60.0% vs 33.3%; NNT = 4) [4]A1b and had a longer interval from last intravenous chemotherapy to death (median 64 vs 40.5 days) [4]A1b. They also received less aggressive end-of-life care (33% vs 54%; NNT = 5) and had longer median survival (11.6 vs 8.9 months) [6]A1b.
Real-world data confirm these benefits. Patients with early palliative care (within 2 months of diagnosis) had a median 35 days on hospice and lower rates of in-hospital death (14%) [85]B3b. A stepped-care model, visits at key transitions plus a QOL trigger, was noninferior for QOL but resulted in fewer hospice days (19.5 vs 34.6) [13]A1b, suggesting that less intensive palliative care may compromise end-of-life continuity. Among veterans, expanded hospice access concurrent with cancer treatment was associated with lower odds of aggressive treatment (AOR 0.66) and ICU use (AOR 0.78), with $266/day lower costs and no survival difference [80]B3b.
Despite these benefits, aggressive care remains common. In the last month of life, 70% of patients had at least one aggressive care criterion [86]B3b; 20% received chemotherapy within 14 days of death [83]A1b; 15% underwent invasive procedures (e.g., intubation, central line) [91]B3b; and 42% died in an acute hospital bed [94]B3b. Hospice consultation was associated with lower ICU admission and less chemotherapy near death [92]B3b. Aggressive care is linked to lower family satisfaction unless the patient dies in a hospice/palliative care unit [93]B3b.
Advance Care Planning and Prognostic Communication
Advance care planning (ACP) should begin early and be revisited. Disease-centred advance directives, detailing NSCLC-specific complications, improve physician concordance with patient wishes (concordance 0.83 vs 0.60 for generic directives) [82]C4. Both recent and past discussions about incurability improve accurate prognostic awareness (AOR 5.08) and reduce preference for life-prolonging treatment (AOR 0.39) [41]B2b. Machine-learning mortality risk tools improve prognostic accuracy (mean change +20.9%) but do not change ACP referral rates (1.3% change) [81]A1b, indicating that accuracy alone is insufficient. The elements of end-of-life discussions (prognosis, do-not-resuscitate orders, hospice, preferred place of death) are not independently associated with outcomes; rather, oncologist compassion and caregiver involvement are key drivers of goal-concordant care [87]B3b.
Terminal Symptom Management
In the final days, management focuses on refractory symptoms. Dyspnea responds to opioids (e.g., 2.5-5 mg every 4 hours as needed) and, if anxiety is present, benzodiazepines. Pain follows the WHO ladder; opioids are first-line for moderate-to-severe pain, with dose titration to comfort. Terminal secretions (death rattle) are managed with anticholinergics such as glycopyrrolate or scopolamine. Delirium is treated with haloperidol 0.5-2 mg or atypical antipsychotics; reversible causes (opioid neurotoxicity, ) should be sought. Non-beneficial treatments, chemotherapy, IV fluids, artificial nutrition, should be withdrawn when burdens outweigh benefits. Clinicians must ensure equity: patients with dementia receive less opioid use (61.8% vs 70.8%), fewer palliative care consultations (2.7% vs 3.8%), and less mechanical ventilation [88]B3b, highlighting the need for consistent end-of-life care regardless of cognitive status.
Pearl: The single most impactful intervention for improving end-of-life care in NSCLC is early, integrated palliative care, it reduces aggressive treatment, improves hospice utilization, and prolongs survival, achieving a 2.7-month median survival gain [6]A1b with an NNT of 5 to avoid aggressive end-of-life care.
| Indicator | Target / Benchmark | Evidence |
|---|---|---|
| Hospice enrollment >1 week | ≥60% | [4]A1b |
| Chemotherapy within 14 days of death | <20% (observed: 20%) | [83]A1b |
| Chemotherapy within 30 days of death | <33.9% (observed) | [89]B3b |
| ICU admission in last month | <10% (observed: 5%) | [94]B3b |
| In-hospital death | <42% (observed); target <20% | [94]B3b |
| Palliative care consultation | ≥50% (observed: 50%) | [86]B3b |
| Invasive procedures in last month | <15% (observed: 15%) | [91]B3b |
| Aggressive care (≥1 criterion) | <33% (observed: 70%) | [86]B3b |
| Advance directive completion | ≥44% (observed: 44% with intervention) | [49]B2b |
Related Pages
Part of the Non-Small Cell Lung Cancer family. Cross-cutting management is split across dedicated child pages:
- , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
- Non-Small Cell Lung Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
- Non-Small Cell Lung Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
- Non-Small Cell Lung Cancer Systemic Therapy , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
- , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
- Non-Small Cell Lung Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease
Pearl: Use these links to hop between management modalities; the parent Non-Small Cell Lung Cancer page carries diagnosis + staging that informs every decision here.
References
- [1]
Reid E, Suneja G, Ambinder RF et al.. “Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30099375 ↗
L1GUIDELINECited in: When to Integrate Palliative Care - [2]
Jazieh AR, Bamefleh H, Demirkazik A et al.. “Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20697125 ↗
L1GUIDELINECited in: When to Integrate Palliative Care - [3]
Pirl WF, Greer JA, Traeger L et al.. “Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22430269 ↗
L1RCTCited in: When to Integrate Palliative Care - [4]
Greer JA, Pirl WF, Jackson VA et al.. “Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 22203758 ↗
L1RCTCited in: When to Integrate Palliative Care, End-of-Life Care and Hospice - [5]
Temel JS, Greer JA, Admane S et al.. “Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21555700 ↗
L1RCTCited in: When to Integrate Palliative Care - [6]
Temel JS, Greer JA, Muzikansky A et al.. “Early palliative care for patients with metastatic non-small-cell lung cancer.” The New England journal of medicine (2010). PMID: 20818875 ↗
L1RCTCited in: When to Integrate Palliative Care, End-of-Life Care and Hospice - [7]
. “Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18678835 ↗
L1SR_MA_RCTCited in: When to Integrate Palliative Care - [8]
Siena S, Crinò L, Danova M et al.. “Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19767314 ↗
L2NON_RANDOMIZED_TRIALCited in: When to Integrate Palliative Care, Palliative Procedures - [9]
Camerini A, Valsuani C, Mazzoni F et al.. “Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19914959 ↗
L2NON_RANDOMIZED_TRIALCited in: When to Integrate Palliative Care - [10]
Temel JS, Jackson VA, Billings JA et al.. “Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17557950 ↗
L2NON_RANDOMIZED_TRIALCited in: When to Integrate Palliative Care - [11]
Smith TJ, Temin S, Alesi ER et al.. “American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22312101 ↗
L2NON_RANDOMIZED_TRIALCited in: When to Integrate Palliative Care - [12]
Greer JA, Temel JS, El-Jawahri A et al.. “Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer: A Multisite Randomized Clinical Trial.” JAMA (2024). PMID: 39259563 ↗
L1RCTCited in: When to Integrate Palliative Care - [13]
Temel JS, Jackson VA, El-Jawahri A et al.. “Stepped Palliative Care for Patients With Advanced Lung Cancer: A Randomized Clinical Trial.” JAMA (2024). PMID: 38824442 ↗
L1RCTCited in: When to Integrate Palliative Care, End-of-Life Care and Hospice - [14]
Allende S, Turcott JG, Verástegui E et al.. “Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial.” The oncologist (2024). PMID: 38558247 ↗
L1RCTCited in: When to Integrate Palliative Care - [15]
Lehman M, Bernard A, See A et al.. “A Randomized Phase 3 Trial of Palliative Radiation Therapy Versus Concurrent Chemotherapy and Palliative Radiation Therapy in Patients With Good Performance Status, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer With Symptoms due to Intrathoracic Disease Who are Not Suitable for Radical Chemo-radiation Therapy: Results of the Trans-Tasman Radiation Oncology Group 11.03 Trial.” Practical radiation oncology (2020). PMID: 33271352 ↗
L1RCTCited in: When to Integrate Palliative Care - [16]
Ettinger DS, Wood DE, Akerley W et al.. “Non-small cell lung cancer, version 1.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 25505215 ↗
L5OTHERCited in: When to Integrate Palliative Care - [17]
Chen M, Yu H, Yang L et al.. “Combined early palliative care for non-small-cell lung cancer patients: a randomized controlled trial in Chongqing, China.” Frontiers in oncology (2023). PMID: 37781179 ↗
L1RCTCited in: When to Integrate Palliative Care - [18]
Kuo JC, Graham DM, Salvarrey A et al.. “A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.” Current oncology (Toronto, Ont.) (2020). PMID: 32489264 ↗
L1RCTCited in: When to Integrate Palliative Care - [19]
Lee KJ, Kwon JH, Kim DH et al.. “Efficacy of Herbal Medicine Therapy Combined With Palliative Chemotherapy in Unresectable Advanced NSCLC: A Systematic Review and Meta-Analysis.” Integrative cancer therapies (2025). PMID: 41103125 ↗
L1SR_MA_RCTCited in: When to Integrate Palliative Care - [20]
Gridelli C, Maione P, Rossi A et al.. “Chemotherapy of advanced NSCLC in special patient population.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16807469 ↗
L5NARRATIVE_REVIEWCited in: When to Integrate Palliative Care - [21]
van Doormaal FF, Di Nisio M, Otten HM et al.. “Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21502549 ↗
L1RCTCited in: Symptom Management - [22]
Belani CP, Brodowicz T, Ciuleanu TE et al.. “Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.” The Lancet. Oncology (2012). PMID: 22336221 ↗
L1RCTCited in: Symptom Management - [23]
Sandler AB, Schiller JH, Gray R et al.. “Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19224857 ↗
L2NON_RANDOMIZED_TRIALCited in: Symptom Management - [24]
Reck M, Barlesi F, Crinò L et al.. “Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 22056855 ↗
L5NARRATIVE_REVIEWCited in: Symptom Management - [25]
Fidler MJ, Argiris A, Patel JD et al.. “The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18381949 ↗
L2NON_RANDOMIZED_TRIALCited in: Symptom Management - [26]
Molins L, Lanuti M, Force S et al.. “Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracic Surgery Lobectomy.” The Journal of surgical research (2020). PMID: 32320894 ↗
L1RCTCited in: Symptom Management - [27]
Meybohm P, Choorapoikayil S, Zinn S et al.. “Removal of EpCAM-positive tumor cells during intraoperative blood salvage- A pivotal multicenter clinical study (REMOVE).” Journal of clinical anesthesia (2025). PMID: 40812168 ↗
L2NON_RANDOMIZED_TRIALCited in: Symptom Management - [28]
Horne ZD, Richman AH, Dohopolski MJ et al.. “Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.” Lung cancer (Amsterdam, Netherlands) (2017). PMID: 29290248 ↗
L2NON_RANDOMIZED_TRIALCited in: Symptom Management - [29]
Ma J, Li X, Zhao S et al.. “Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis.” BMC cancer (2021). PMID: 33941112 ↗
L1SR_MA_RCTCited in: Symptom Management - [30]
Hireche K, Canaud L, Lounes Y et al.. “Thoracoscopic Versus Open Lobectomy After Induction Therapy for Nonsmall Cell Lung Cancer: New Study Results and Meta-analysis.” The Journal of surgical research (2022). PMID: 35465975 ↗
L2SR_COHORTCited in: Symptom Management - [31]
Zeng W, Zhang W, Zhang J et al.. “Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small cell lung cancer.” World journal of surgical oncology (2020). PMID: 32106856 ↗
L2SR_COHORTCited in: Symptom Management - [32]
Lau BC, Wu YF, No HJ et al.. “Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2023). PMID: 37085030 ↗
L2PROSPECTIVE_COHORTCited in: Symptom Management - [33]
Urbanic JJ, Wang X, Bogart JA et al.. “Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).” International journal of radiation oncology, biology, physics (2018). PMID: 29487024 ↗
L4PHASE_1_TRIALCited in: Symptom Management - [34]
Greystoke A, Steele N, Arkenau HT et al.. “SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.” British journal of cancer (2017). PMID: 28950288 ↗
L4PHASE_1_TRIALCited in: Symptom Management - [35]
Wang Z, Pang L, Tang J et al.. “Video-assisted thoracoscopic surgery versus muscle-sparing thoracotomy for non-small cell lung cancer: a systematic review and meta-analysis.” BMC surgery (2019). PMID: 31615490 ↗
L2SR_COHORTCited in: Symptom Management - [36]
Huang L, Huang X, Zhou Y et al.. “Robotic-assisted versus video-assisted thoracoscopic anatomical pulmonary resection in elderly patients with lung cancer: A propensity score-matched comparison of short-term outcomes.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42061191 ↗
L3COHORTCited in: Symptom Management - [37]
Li HJ, Ding JY, Nie Q et al.. “Advantages of robotic-assisted thoracic surgery after neoadjuvant therapy in NSCLC: A propensity score-matched analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2025). PMID: 40250266 ↗
L3COHORTCited in: Symptom Management - [38]
Gulikers JL, Otten LS, Hendriks LEL et al.. “Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.” British journal of cancer (2024). PMID: 38862741 ↗
L4COHORTCited in: Symptom Management - [39]
Huang YW, Zhang Y, Li ZP et al.. “Association between a four-parameter inflammatory index and all-cause mortality in critical ill patients with non-traumatic subarachnoid hemorrhage: a retrospective analysis of the MIMIC-IV database (2012-2019).” Frontiers in immunology (2023). PMID: 37936706 ↗
L3COHORTCited in: Symptom Management - [40]
Farha N, Faisal MS, Allende DS et al.. “Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center.” The oncologist (2023). PMID: 36905577 ↗
L4COHORTCited in: Symptom Management - [41]
Hasegawa T, Okuyama T, Uemura T et al.. “Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study.” The oncologist (2022). PMID: 36067268 ↗
L2PROSPECTIVE_COHORTCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [42]
Milbury K, Li Y, Durrani S et al.. “A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial.” The oncologist (2020). PMID: 32621630 ↗
L4RCTCited in: Psychosocial, Spiritual, and Caregiver Support - [43]
Li Y, Ling L, Zhanyu P. “Effect of Wellness Education on Quality of Life of Patients With Non-Small Cell Lung Cancer Treated With First-Line Icotinib and on Their Family Caregivers.” Integrative cancer therapies (2019). PMID: 31043093 ↗
L1RCTCited in: Psychosocial, Spiritual, and Caregiver Support - [44]
Gustafson DH, DuBenske LL, Namkoong K et al.. “An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial.” Cancer (2013). PMID: 23355273 ↗
L1RCTCited in: Psychosocial, Spiritual, and Caregiver Support - [45]
Ikander T, Jeppesen SS, Hansen O et al.. “Patients and family caregivers report high treatment expectations during palliative chemotherapy: a longitudinal prospective study.” BMC palliative care (2021). PMID: 33637063 ↗
L3COHORTCited in: Psychosocial, Spiritual, and Caregiver Support - [46]
Viñolas NN, Garcia-Campelo R, Majem M et al.. “Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study.” BMC psychology (2020). PMID: 33228796 ↗
L3COHORTCited in: Psychosocial, Spiritual, and Caregiver Support - [47]
Yanwei L, Minghui F, Manman Q et al.. “Influence of wellness education on first-line icotinib hydrochloride patients with stage IV non-small cell lung cancer and their family caregivers.” Current problems in cancer (2018). PMID: 29731164 ↗
L1RCTCited in: Psychosocial, Spiritual, and Caregiver Support - [48]
Nguyen HQ, Ruel N, Macias M et al.. “Translation and Evaluation of a Lung Cancer, Palliative Care Intervention for Community Practice.” Journal of pain and symptom management (2018). PMID: 30076966 ↗
L2NON_RANDOMIZED_TRIALCited in: Psychosocial, Spiritual, and Caregiver Support - [49]
Ferrell B, Sun V, Hurria A et al.. “Interdisciplinary Palliative Care for Patients With Lung Cancer.” Journal of pain and symptom management (2015). PMID: 26296261 ↗
L2NON_RANDOMIZED_TRIALCited in: Psychosocial, Spiritual, and Caregiver Support, End-of-Life Care and Hospice - [50]
Milbury K, Mallaiah S, Lopez G et al.. “Vivekananda Yoga Program for Patients With Advanced Lung Cancer and Their Family Caregivers.” Integrative cancer therapies (2015). PMID: 25917816 ↗
L2NON_RANDOMIZED_TRIALCited in: Psychosocial, Spiritual, and Caregiver Support - [51]
Milbury K, Engle R, Tsao A et al.. “Pilot Testing of a Brief Couple-Based Mind-Body Intervention for Patients With Metastatic Non-Small Cell Lung Cancer and Their Partners.” Journal of pain and symptom management (2017). PMID: 29208478 ↗
L4NON_RANDOMIZED_TRIALCited in: Psychosocial, Spiritual, and Caregiver Support - [52]
Bhattacharya P, Dessain SK, Evans TL. “Palliative Care in Lung Cancer: When to Start.” Current oncology reports (2018). PMID: 30414010 ↗
L5NARRATIVE_REVIEWCited in: Psychosocial, Spiritual, and Caregiver Support - [53]
Chandrasekar D, Tribett E, Ramchandran K. “Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer.” Current treatment options in oncology (2016). PMID: 27032645 ↗
L5NARRATIVE_REVIEWCited in: Psychosocial, Spiritual, and Caregiver Support - [54]
Kaptein AA, Kobayashi K, Matsuda A et al.. “We're in this together: Patients', caregivers' and health care providers' illness perceptions about non-small-cell lung cancer (NSCLC).” Lung cancer (Amsterdam, Netherlands) (2015). PMID: 26520188 ↗
L5NARRATIVE_REVIEWCited in: Psychosocial, Spiritual, and Caregiver Support - [55]
Lissoni P, Messina G, Parolini D et al.. “A spiritual approach in the treatment of cancer: relation between faith score and response to chemotherapy in advanced non-small cell lung cancer patients.” In vivo (Athens, Greece) (2008). PMID: 18853749 ↗
L2NON_RANDOMIZED_TRIALCited in: Psychosocial, Spiritual, and Caregiver Support - [56]
Zhu S, Yang C, Mei W et al.. “Caregiver burden for informal caregivers of patients after surgical treatment of early-stage lung cancer.” Journal of clinical nursing (2022). PMID: 35869414 ↗
L3CROSS_SECTIONALCited in: Psychosocial, Spiritual, and Caregiver Support - [57]
Yang Y, Liu L, Chen J et al.. “Does caring for patients with advanced non-small cell lung cancer affect health-related quality of life of caregivers? A multicenter, cross-sectional study.” BMC public health (2024). PMID: 38238722 ↗
L3CROSS_SECTIONALCited in: Psychosocial, Spiritual, and Caregiver Support - [58]
Ma L, Zhu K, Shi C et al.. “Association between the patients' symptom burden and their family caregivers' benefit finding in non-small cell lung cancer receiving combined chemotherapy.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023). PMID: 36729306 ↗
L3CROSS_SECTIONALCited in: Psychosocial, Spiritual, and Caregiver Support - [59]
Orr LD, Vanderpoel J, Vadagam P et al.. “Patient, care partner, and provider voice in treatment decision-making for non-small cell lung cancer.” Patient education and counseling (2025). PMID: 40215576 ↗
L3CROSS_SECTIONALCited in: Psychosocial, Spiritual, and Caregiver Support - [60]
Wood R, Taylor-Stokes G, Lees M. “The humanistic burden associated with caring for patients with advanced non-small cell lung cancer (NSCLC) in three European countries-a real-world survey of caregivers.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2018). PMID: 30121787 ↗
L3CROSS_SECTIONALCited in: Psychosocial, Spiritual, and Caregiver Support - [61]
Liao Z, Rivin Del Campo E, Salem A et al.. “Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak.” Lung cancer (Amsterdam, Netherlands) (2020). PMID: 32585497 ↗
L2SR_COHORTCited in: Palliative Procedures - [62]
Duggan KJ, Wiltshire J, Strutt R et al.. “Palliative care and psychosocial care in metastatic non-small cell lung cancer: factors affecting utilisation of services and impact on patient survival.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2018). PMID: 30066201 ↗
L1RCTCited in: Palliative Procedures - [63]
Mulvenna P, Nankivell M, Barton R et al.. “Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.” Lancet (London, England) (2016). PMID: 27604504 ↗
L1RCTCited in: Palliative Procedures - [64]
Jeremic B, Fidarova E, Sharma V et al.. “The International Atomic Energy Agency (IAEA) randomized trial of palliative treatment of incurable locally advanced non small cell lung cancer (NSCLC) using radiotherapy (RT) and chemotherapy (CHT) in limited resource setting.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2015). PMID: 26163093 ↗
L1RCTCited in: Palliative Procedures - [65]
Strøm HH, Bremnes RM, Sundstrøm SH et al.. “Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2014). PMID: 24807158 ↗
L1RCTCited in: Palliative Procedures - [66]
Strøm HH, Bremnes RM, Sundstrøm SH et al.. “Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.” British journal of cancer (2013). PMID: 23963145 ↗
L1RCTCited in: Palliative Procedures - [67]
Zhou D, Zhao N, Xu H et al.. “The safety and efficacy of immunotherapy and palliative radiotherapy in patients with metastatic non-small cell lung cancer: a systematic review and meta-analysis of 13 prospective studies.” Expert review of anticancer therapy (2023). PMID: 37272502 ↗
L1SR_MA_RCTCited in: Palliative Procedures - [68]
Paappanen V, Järvenpää H, Jukkola A et al.. “Impact of Treatment Decisions on Survival Outcomes in Elderly Patients With Non-Small Cell Lung Cancer: A Retrospective Real-World Study.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2025). PMID: 41027332 ↗
L3RETROSPECTIVE_COHORTCited in: Palliative Procedures - [69]
Xu Y, Trach C, Tessier T et al.. “Outcomes of patients receiving urgent palliative radiotherapy for advanced lung cancer: an observational study.” BMC palliative care (2024). PMID: 39709422 ↗
L3COHORTCited in: Palliative Procedures - [70]
Ren J, Huang J, Wang Z et al.. “Acceptability of palliative sleeve lobectomy with microscopic margin disease in patients with non-small cell lung cancer: A retrospective study.” Surgery (2024). PMID: 39455386 ↗
L3COHORTCited in: Palliative Procedures - [71]
Quiñones-Avila V, Ortiz-Ortiz KJ, Ríos-Motta R et al.. “Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer in Puerto Rico.” BMC palliative care (2021). PMID: 34389004 ↗
L3RETROSPECTIVE_COHORTCited in: Palliative Procedures - [72]
Buergy D, Würschmidt F, Gkika E et al.. “Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis.” International journal of cancer (2021). PMID: 33682927 ↗
L4RETROSPECTIVE_COHORTCited in: Palliative Procedures - [73]
Nieder C, Imingen KS, Mannsåker B et al.. “Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.” Radiation oncology (London, England) (2020). PMID: 32357936 ↗
L3COHORTCited in: Palliative Procedures - [74]
Støchkel Frank M, Schou Nørøxe D, Nygård L et al.. “Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while?” BMC palliative care (2018). PMID: 29304789 ↗
L4COHORTCited in: Palliative Procedures - [75]
Kiss N, Isenring E, Gough K et al.. “The prevalence of weight loss during (chemo)radiotherapy treatment for lung cancer and associated patient- and treatment-related factors.” Clinical nutrition (Edinburgh, Scotland) (2013). PMID: 24325888 ↗
L3COHORTCited in: Palliative Procedures - [76]
Cañón V, López-Guerra JL, Arteagoitia A et al.. “Impact of Radiation Dose on the Survival of Patients With Non-small Cell Lung Cancer Treated With Palliative Intent: Results of a Multicenter Prospective Study.” Anticancer research (2024). PMID: 39626908 ↗
L3COHORTCited in: Palliative Procedures - [77]
Mehnert E, Möller FS, Hofbauer C et al.. “Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment.” BMC cancer (2024). PMID: 39574021 ↗
L3COHORTCited in: Palliative Procedures - [78]
Nieder C, Imingen KS. “Palliative Radiotherapy for Non-metastatic Non-small-cell Lung Cancer: Impact of Blood Test Results on Survival.” In vivo (Athens, Greece) (2023). PMID: 36881095 ↗
L3RETROSPECTIVE_COHORTCited in: Palliative Procedures - [79]
Soror T, Kovács G, Wecker S et al.. “Palliative treatment with high-dose-rate endobronchial interventional radiotherapy (Brachytherapy) for lung cancer patients.” Brachytherapy (2021). PMID: 34429246 ↗
L3COHORTCited in: Palliative Procedures - [80]
Mor V, Wagner TH, Levy C et al.. “Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer.” JAMA oncology (2019). PMID: 30920603 ↗
L3COHORTCited in: End-of-Life Care and Hospice - [81]
Parikh RB, Ferrell WJ, Girard A et al.. “The Impact of Machine Learning Mortality Risk Prediction on Clinician Prognostic Accuracy and Decision Support: A Randomized Vignette Study.” Medical decision making : an international journal of the Society for Medical Decision Making (2025). PMID: 40613383 ↗
L1RCTCited in: End-of-Life Care and Hospice - [82]
Koenig JFL, Asendorf T, Simon A et al.. “"SpezPat"- common advance directives versus disease-centred advance directives: a randomised controlled pilot study on the impact on physicians' understanding of non-small cell lung cancer patients' end-of-life decisions.” BMC palliative care (2022). PMID: 36167565 ↗
L4RCTCited in: End-of-Life Care and Hospice - [83]
Fujisawa D, Temel JS, Traeger L et al.. “Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life.” Psycho-oncology (2015). PMID: 25959002 ↗
L1RCTCited in: End-of-Life Care and Hospice - [84]
Beijer S, van Rossum E, Hupperets PS et al.. “Application of adenosine 5'-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial.” BMC public health (2007). PMID: 17210069 ↗
L1RCTCited in: End-of-Life Care and Hospice - [85]
Oswalt CJ, Nakatani MM, Troy J et al.. “Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer.” Journal of pain and symptom management (2024). PMID: 39002711 ↗
L3COHORTCited in: End-of-Life Care and Hospice - [86]
Martin A, Carton M, Thery L et al.. “Palliative care integration and end-of-life care intensity for patients with NSCLC.” Lung cancer (Amsterdam, Netherlands) (2024). PMID: 38728972 ↗
L3COHORTCited in: End-of-Life Care and Hospice - [87]
Hasegawa T, Okuyama T, Uemura T et al.. “Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.” The oncologist (2024). PMID: 37669003 ↗
L3COHORTCited in: End-of-Life Care and Hospice - [88]
Hirooka K, Okumura Y, Matsumoto S et al.. “Quality of End-of-Life in Cancer Patients With Dementia: Using A Nationwide Inpatient Database.” Journal of pain and symptom management (2022). PMID: 35367609 ↗
L3COHORTCited in: End-of-Life Care and Hospice - [89]
Casebeer A, Antol DD, DeClue RW et al.. “The Relationship Between Guideline-Recommended Initiation of Therapy, Outcomes, and Cost for Patients with Metastatic Non-Small Cell Lung Cancer.” Journal of managed care & specialty pharmacy (2018). PMID: 29799325 ↗
L3COHORTCited in: End-of-Life Care and Hospice - [90]
Collins A, Sundararajan V, Burchell J et al.. “Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer.” Journal of pain and symptom management (2018). PMID: 29608934 ↗
L4COHORTCited in: End-of-Life Care and Hospice - [91]
Tukey MH, Faricy-Anderson K, Corneau E et al.. “Procedural Aggressiveness in Veterans with Advanced Non-Small-Cell Lung Cancer at the End of Life.” Journal of palliative medicine (2017). PMID: 29265906 ↗
L3RETROSPECTIVE_COHORTCited in: End-of-Life Care and Hospice - [92]
Yoo SH, Keam B, Kim M et al.. “The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer.” Cancer research and treatment (2017). PMID: 28707460 ↗
L3COHORTCited in: End-of-Life Care and Hospice - [93]
Ersek M, Miller SC, Wagner TH et al.. “Association between aggressive care and bereaved families' evaluation of end-of-life care for veterans with non-small cell lung cancer who died in Veterans Affairs facilities.” Cancer (2017). PMID: 28419414 ↗
L3COHORTCited in: End-of-Life Care and Hospice - [94]
Philip J, Hudson P, Bostanci A et al.. “Metastatic non-small cell lung cancer: a benchmark for quality end-of-life cancer care?” The Medical journal of Australia (2015). PMID: 25669476 ↗
L3RETROSPECTIVE_COHORTCited in: End-of-Life Care and Hospice